Talphera | 8-K: FY2025 Q3 Revenue: USD 1 K

Revenue: As of FY2025 Q3, the actual value is USD 1 K.

EPS: As of FY2025 Q3, the actual value is USD -0.11, meeting the estimate of USD -0.11.

EBIT: As of FY2025 Q3, the actual value is USD -3.503 M.

Cash and Investments

• Cash and investments at September 30, 2025, were $21.3 million.

Operating Costs and Expenses

• Combined R&D and SG&A expenses for Q3 2025 totaled $3.4 million, down from $3.7 million in Q3 2024. Excluding non-cash stock-based compensation, these amounts were $3.3 million for Q3 2025, compared to $3.5 million for Q3 2024.

Net Loss

• Net loss from continuing operations for Q3 2025 was $4.4 million, compared to $3.4 million in Q3 2024, primarily due to an increase in the fair value of the Company’s warrant liability.
• Net loss attributable to common shareholders for Q3 2025 was $4.4 million, or $0.11 per basic and diluted share, compared to a net loss of $3.4 million, or $0.13 per basic and diluted share, for Q3 2024.

Total Assets and Liabilities

• Total assets as of September 30, 2025, were $30.7 million, compared to $18.2 million as of December 31, 2024.
• Total liabilities as of September 30, 2025, were $11.6 million, compared to $10.2 million as of December 31, 2024.

Outlook / Guidance

• Talphera expects cash operating expenses, excluding stock-based compensation, to be in the range of $14 million to $15 million in 2025, a reduction from the previously provided range of $16 million to $17 million, with the difference expected to be realized in the first quarter of 2026.
• The company anticipates sufficient cash through a potential PMA approval of Niyad in late 2026, supported by current cash balance and conditional future tranches from previous financings.
• The NEPHRO study is expected to complete enrollment in the first half of 2026, with four new target profile sites to be activated in Q4 2025.